Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Document › Details

Biotie Therapies Corporation. (11/14/08). "Press Release: The Acquisition of the Pharmaceutical Development Company Elbion GmbH Completed".

Organisations Organisation Elbion GmbH
  Today Biocrea GmbH
  Group Biocrea GmbH
  Organisation 2 Biotie Therapies Corporation
  Group Biotie (Group)
Product Product drug discovery
Index term Index term Elbion–Biotie: investment, 200810–200811 acquisition merger in shares w Elbion owners receiving 32.3% of Biotie issued share capital
     


Biotie Therapies Corp. ("Biotie" or the "Company") has entered into an agreement with elbion NV on the acquisition of its fully owned subsidiary, elbion GmbH (the "Transaction"). To complete the Transaction, the Board of Directors of Biotie has proposed to the General Meeting of Shareholders of Biotie to be convened on 14 November 2008 (the "General Meeting of Shareholder") that the General Meeting would resolve, in deviation from the shareholders' pre-emptive subscription right: (i) to offer 46,802,967 new shares (the "Exchange Shares") to be subscribed by elbion NV as consideration for one (1) share in elbion GmbH (the "Exchange Offer") and (ii) in connection with the Exchange Offer to offer up to 7,305,733 new shares to be subscribed by certain funds held or managed by Burrill & Company, TVM Capital and AGF Private Equity (the "Offer Shares", the "Offering") (the Offer Shares and the Exchange Shares together, the "Shares"). Biotie has disclosed the agreement, the details of the transaction and the activities of the combined entity in a stock exchange release published on 24 October 2008.

The Transaction was subject to the resolutions of the General Meeting of Biotie on the share issue and the election of new board members to the Board of Biotie. These resolutions have been made in the Extraordinary General Meeting of Biotie held today. Biotie has published a stock exchange release earlier today regarding the resolutions of the General Meeting. The notice to the Extraordinary General Meeting and the proposals of the Board have been disclosed in a stock exchange release on 24 October 2008.

As announced earlier, as consideration, Biotie has issued 46,802,967 new shares to elbion NV for subscription. In connection with the transaction, certain shareholders of elbion NV have invested an aggregate amount of EUR 3.3 million into the combined entity by subscribing 7,305,733 new shares of Biotie.

The issue of the consideration shares in the acquisition of elbion GmbH and their subscriptions and payment have been completed today, and the title to the share capital of elbion GmbH has been transferred to Biotie. The new shares of Biotie have been notified for registration to the Trade Register. The new shares shall be registered approximately on 17 November 2008 and admitted to public trading on the main list of NASDAQ OMX Helsinki Ltd on Tuesday, 18 November 2008.

In the Combination Agreement elbion NV has agreed not to transfer the Shares in Biotie for which it has subscribed in connection with the Exchange Offering for 12 months as of the completion of the Exchange Offering, except for the transfers between the shareholders or affiliates of elbion NV and to certain directors of elbion GmbH, provided that the corresponding transfer restriction applies to the said entities and parties. Funds that have subscribed for Shares in the Offering: TVM Life Science Ventures VI GmbH & Co. KG, FCPI AGF Innovation 5, FCPI AGF Innovation 4, Burrill Life Science Capital Fund L.P., Burrill Indiana Life Science Capital Fund L.P. and TVM Life Science Ventures VI L.P. have agreed that a corresponding transfer restriction shall apply to the said funds.

The number of the consideration shares offered to elbion NV represents 32.43 per cent of Biotie's issued share capital and votes attaching thereto after the transaction. The shares subscribed by certain shareholders of elbion NV represent, respectively, 5.06 per cent of the Company's issued share capital and votes attaching thereto after the transaction. elbion NV has been granted an exemption from the obligation to made a public tender offer in accordance with chapter 6, section 10 of the Finnish Securities Markets Act and elbion NV is not obligated to make an offer for all shares of Biotie even though its holdings exceed 3/10 of the voting rights attached to all shares in Biotie. The Prerequisite for the exemption was that the holdings of elbion NV of voting rights in Biotie referred to in Chapter 6, Section 10 of the Finnish Securities Markets Act shall decrease to or below 3/10 within nine months after the Shares issued in connection with the Exchange Offer have been entered into the Trade Register.

Following the registration of the issued shares, Biotie has the aggregate of 144.320.560 shares and the aggregate share capital of EUR 44.290.678,10.

Turku, 14 November 2008

Biotie Therapies Corp.
Board of Directors

For further information, please contact:
Timo Veromaa, President and CEO, Biotie Therapies Corp
tel. +358 2 274 8900, e-mail: timo.veromaa@biotie.com
www.biotie.com

   
Record changed: 2016-05-31

Advertisement

Picture AB Sciex Berliner LCMSMS Symposium 2017 Middle 600x60px

More documents for Biocrea GmbH


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wptb




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 120x240px wpctoc Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px